ストックスクリーナーアプリを入手
0.9899
5.34%
0.0502
前日終値:
$0.9397
開ける：
$0.94
24時間の取引高:
30,705
Relative Volume:
0.14
時価総額：
$16.36M
収益：
-
当期純損益:
$-52.53M
株価収益率:
-0.2705
EPS:
-3.66
ネットキャッシュフロー:
$-39.93M
1週間 パフォーマンス:
+2.05%
1か月 パフォーマンス:
-45.76%
6か月 パフォーマンス:
-29.29%
1年 パフォーマンス:
-33.11%
1日の値動き範囲:
$0.94
$1.01
1週間の範囲:
$0.9102
$1.0252
52週間の値動き範囲:
$0.8531
$3.10
Unity Biotechnology Inc Stock (UBX) Company Profile
名前
Unity Biotechnology Inc
セクター
電話
(650) 416-1192
住所
285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA
UBX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
UBX
Unity Biotechnology Inc
|
0.9899 | 16.36M | 0 | -52.53M | -39.93M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.30 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
583.10 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.94 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.79 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
253.84 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Unity Biotechnology Inc Stock (UBX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-22 | 開始されました | Rodman & Renshaw | Buy |
| 2023-11-16 | アップグレード | Wedbush | Neutral → Outperform |
| 2022-01-04 | アップグレード | ROTH Capital | Neutral → Buy |
| 2021-11-10 | アップグレード | Mizuho | Neutral → Buy |
| 2021-06-28 | アップグレード | Citigroup | Sell → Buy |
| 2021-06-07 | 開始されました | H.C. Wainwright | Buy |
| 2021-02-16 | ダウングレード | Citigroup | Neutral → Sell |
| 2020-08-18 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-08-18 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-08-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-08-17 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2020-07-28 | 開始されました | ROTH Capital | Buy |
| 2019-12-12 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-03-07 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-09-07 | 開始されました | Mizuho | Buy |
| 2018-05-29 | 開始されました | Citigroup | Buy |
| 2018-05-29 | 開始されました | Goldman | Neutral |
| 2018-05-29 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Unity Biotechnology Inc (UBX) 最新ニュース
Unity Biotechnology stock hits 52-week low at $0.94 By Investing.com - Investing.com Canada
Unity Biotechnology stock hits 52-week low at $0.94 - Investing.com
Unity Biotechnology CFO Lynne Sullivan sells $22,523 in stock By Investing.com - Investing.com Australia
Unity Biotechnology CFO Lynne Sullivan sells $22,523 in stock - Investing.com
Unity Biotechnology Executives Sell Shares for Tax Obligations - TradingView
HC Wainwright Has Pessimistic Outlook of UBX FY2026 Earnings - The AM Reporter
What is HC Wainwright’s Estimate for UBX FY2026 Earnings? - Defense World
Unity Biotechnology (NASDAQ:UBX) Price Target Lowered to $4.00 at Chardan Capital - Defense World
H.C. Wainwright cuts Unity Biotechnology target to $4; keeps buy rating - Investing.com Australia
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study - MSN
Unity Biotechnology price target lowered to $4 from $6 at Chardan - TipRanks
H.C. Wainwright cuts Unity Biotechnology target to $4; keeps buy rating By Investing.com - Investing.com South Africa
UNITY Biotechnology tanks on mixed results for eye disease drug - The Pharma Letter
Mizuho maintains Unity Biotechnology Outperform rating By Investing.com - Investing.com South Africa
Chardan Cuts Price Target on Unity Biotechnology to $4 From $6, Keeps Buy Rating - Marketscreener.com
Mizuho maintains Unity Biotechnology Outperform rating - Investing.com India
Unity Biotechnology (NASDAQ:UBX) Price Target Cut to $4.00 by Analysts at HC Wainwright - Defense World
UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE - EIN News
Sector Update: Health Care Stocks Rise Late Afternoon - TradingView
Sector Update: Health Care - TradingView
Unity Biotechnology Shares Decline After Diabetic Edema Treatment Misses Primary Endpoint - Marketscreener.com
UNITY Biotechnology tanks after failing to meet goal in eye disorder treatment trial - MSN
HC Wainwright Adjusts Unity Biotechnology Price Target to $4 From $8, Maintains Buy Rating - Marketscreener.com
UNITY Biotechnology Shares Drop 33% After Phase 2b Trial Data on UBX1325 in Diabetic Macular Edema - Yahoo
Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls - Benzinga
Unity Biotechnology, Inc. Announces Topline Results from the ASPIRE Phase 2B Study in Diabetic Macular Edema - MarketScreener
UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema - GlobeNewswire
New DME Treatment Matches Standard Care: Phase 2b Shows Promising Vision Gains - Stock Titan
China’s Plans for a $900 Billion Space Project, but Can It Catch Up to SpaceX? - The Globe and Mail
UNITY Biotechnology's UBX1325: A Game Changer for DME Treatment? - AInvest
UNITY Biotechnology to Host Virtual Investor Event Featuring Phase 2b ASPIRE Study Results for UBX1325 in Diabetic Macular Edema - Nasdaq
UNITY Biotechnology to Host Virtual Investor Event to - GlobeNewswire
Key Phase 2b Data Coming: UNITY's DME Treatment Could Transform Eye Disease Care - Stock Titan
Where Will QuantumScape Stock Be in 3 Years? - The Globe and Mail
This Micro Cap Continues This Week's Dominance Amid New CEO Appointment - The Globe and Mail
RECONAFRICA ANNOUNCES ACCELERATION OF DRILLING INTO Q2 2025 AND A CORPORATE UPDATE - The Globe and Mail
3 Reasons to Avoid AIR and 1 Stock to Buy Instead - The Globe and Mail
This Media Stock Is Finding Serious Success Prior To Opening Bell - The Globe and Mail
Unity Biotechnology Reports 2024 Financial Results and Updates - MSN
Unity Biotechnology announces upcoming trial data and new board of directors member - Ophthalmology Times
Chardan Capital Has Bullish Outlook for UBX FY2025 Earnings - Defense World
HC Wainwright Has Strong Estimate for UBX FY2025 Earnings - Defense World
Analysts Issue Forecasts for UBX Q1 Earnings - Defense World
Unity Biotechnology (NASDAQ:UBX) Receives “Buy” Rating from Chardan Capital - Defense World
UNITY Biotechnology appoints Yehia Hashad to its board -March 10, 2025 at 10:40 am EDT - Marketscreener.com
Unity Biotechnology Inc (UBX) 財務データ
収益
当期純利益
現金流量
EPS
1.75%
2.22%
大文字化:
|
ボリューム (24 時間):